Kymera Therapeutics, Inc. (KYMR)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Collaboration revenue | 11,476 | 3,741 | ||
| Research and development | 78,388 | 60,410 | ||
| Impairment of long-lived assets | - | - | ||
| General and administrative | 17,645 | 15,455 | ||
| Total operating expenses | 96,033 | 75,865 | ||
| Loss from operations | -84,557 | -72,124 | ||
| Interest and other income | 8,051 | 9,697 | ||
| Interest and other expense | 108 | 60 | ||
| Total other income | 7,943 | 9,637 | ||
| Net loss | -76,614 | -62,487 | ||
| Unrealized gain (loss) on marketable securities | 337 | 4,030 | ||
| Total comprehensive loss | -76,277 | -58,457 | ||
| Net loss per share, basic | -0.95 | -0.82 | ||
| Net loss per share, diluted | -0.95 | -0.82 | ||
| Weighted average common shares outstanding, basic | 80,449,405 | 76,125,975 | ||
| Weighted average common shares outstanding, diluted | 80,449,405 | 76,125,975 | ||